Phibro Animal Health (PAHC) Expected to Announce Quarterly Earnings on Wednesday

Phibro Animal Health (NASDAQ:PAHC) is anticipated to announce its Q2 2026 results after the market closes on Wednesday, February 4th. Analysts expect the company to announce earnings of $0.69 per share and revenue of $355.6360 million for the quarter. Phibro Animal Health has set its FY 2026 guidance at 2.640-2.810 EPS. Investors may visit the the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, February 5, 2026 at 9:00 AM ET.

Phibro Animal Health (NASDAQ:PAHC) last released its quarterly earnings results on Wednesday, November 5th. The company reported $0.73 earnings per share for the quarter, topping the consensus estimate of $0.58 by $0.15. Phibro Animal Health had a net margin of 4.85% and a return on equity of 36.26%. The business had revenue of $363.89 million for the quarter, compared to the consensus estimate of $345.44 million. On average, analysts expect Phibro Animal Health to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Phibro Animal Health Trading Up 4.4%

Shares of PAHC stock opened at $41.91 on Tuesday. The company has a debt-to-equity ratio of 2.32, a current ratio of 3.09 and a quick ratio of 1.35. The company has a market cap of $1.70 billion, a price-to-earnings ratio of 25.25, a PEG ratio of 1.14 and a beta of 0.80. Phibro Animal Health has a 1 year low of $16.16 and a 1 year high of $46.42. The firm has a fifty day moving average price of $39.85 and a 200-day moving average price of $37.96.

Insider Transactions at Phibro Animal Health

In related news, CEO Jack Bendheim sold 6,693 shares of the business’s stock in a transaction that occurred on Friday, January 30th. The stock was sold at an average price of $40.09, for a total value of $268,322.37. Following the transaction, the chief executive officer directly owned 31,980 shares of the company’s stock, valued at approximately $1,282,078.20. The trade was a 17.31% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Over the last 90 days, insiders sold 161,060 shares of company stock worth $6,945,844. 50.13% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Phibro Animal Health

Several hedge funds have recently modified their holdings of PAHC. iSAM Funds UK Ltd purchased a new position in Phibro Animal Health during the third quarter valued at $61,000. EverSource Wealth Advisors LLC boosted its holdings in shares of Phibro Animal Health by 7,671.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,720 shares of the company’s stock valued at $69,000 after purchasing an additional 2,685 shares during the last quarter. Advisory Services Network LLC bought a new position in shares of Phibro Animal Health during the 3rd quarter valued at about $96,000. Tower Research Capital LLC TRC grew its position in shares of Phibro Animal Health by 768.2% during the second quarter. Tower Research Capital LLC TRC now owns 4,610 shares of the company’s stock valued at $118,000 after purchasing an additional 4,079 shares in the last quarter. Finally, State of Wyoming increased its holdings in shares of Phibro Animal Health by 148.8% in the second quarter. State of Wyoming now owns 6,608 shares of the company’s stock worth $169,000 after purchasing an additional 3,952 shares during the last quarter. Hedge funds and other institutional investors own 99.34% of the company’s stock.

Wall Street Analyst Weigh In

PAHC has been the subject of several recent research reports. Weiss Ratings reissued a “buy (b-)” rating on shares of Phibro Animal Health in a report on Monday, December 29th. Zacks Research raised Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, December 9th. Finally, JPMorgan Chase & Co. increased their target price on shares of Phibro Animal Health from $45.00 to $50.00 and gave the stock an “overweight” rating in a report on Friday, November 7th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $31.40.

About Phibro Animal Health

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.